Ruxolitinib Phosphate
Myelodysplastic/Myeloproliferative Neoplasm
Explore 42 assets in Myelodysplastic/Myeloproliferative Neoplasm →Floatz Rating
B59/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02257138CT.gov Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01164163CT.gov INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myelodysplastic/Myeloproliferative Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ruxolitinib Phosphate (this asset) | M.D. Anderson Cancer Center | P1/2 | B · 59 |
| Etoposide | M.D. Anderson Cancer Center | P3 | BBB |
| Cyclosporin A | Memorial Sloan Kettering Cancer Center | P3 | BBB |
| Melphalan | M.D. Anderson Cancer Center | P2/3 | BBB |
| Cytarabine | Fred Hutchinson Cancer Center | P3 | BBB |
| Busulfanum | Jacqueline Garcia, MD | P2/3 | BBB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | M.D. Anderson Cancer Center | P2/3 | BBB |
| Fludarabine | Fred Hutchinson Cancer Center | P3 | BBB |
| Tacrolimus | M.D. Anderson Cancer Center | P2 | BBB |
+42 more in the Myelodysplastic/Myeloproliferative Neoplasm cohort
Other indications for Ruxolitinib Phosphate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma | — | P2 | BB · 64 |
| Acute Myeloid Leukemia | — | P2 | B · 56 |
| Myelodysplastic Syndrome | — | P2 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ruxolitinib Phosphate in Myelodysplastic/Myeloproliferative Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ruxolitinib-phosphate-myelodysplasticmyeloproliferative-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →